Published in Hum Mol Genet on July 16, 2008
Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience (2011) 1.62
Intercellular (mis)communication in neurodegenerative disease. Neuron (2012) 1.31
Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Mol Neurodegener (2008) 1.20
Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci (2009) 1.14
Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp (2012) 1.07
Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms. ASN Neuro (2010) 1.03
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet (2010) 0.96
Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J (2013) 0.90
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol (2010) 0.89
Mouse models of polyglutamine diseases: review and data table. Part I. Mol Neurobiol (2012) 0.84
Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling. Mol Neurobiol (2015) 0.83
Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro (2011) 0.82
Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo. J Biol Chem (2015) 0.79
Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element. J Neurosci (2012) 0.79
Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia. Hum Mol Genet (2015) 0.78
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease. Mech Ageing Dev (2016) 0.77
Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease. Front Cell Neurosci (2016) 0.76
Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin. Sci Rep (2015) 0.75
Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. PLoS One (2013) 0.75
Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 7.13
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 6.45
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell (2004) 5.67
Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology (2002) 5.40
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 4.79
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet (2003) 4.76
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet (1999) 4.06
Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature (1997) 4.01
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell (1994) 3.52
Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav (2005) 3.47
Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab (2006) 3.38
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet (2000) 3.07
Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78
Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology (2003) 2.73
Lessons from animal models of Huntington's disease. Trends Genet (2002) 2.54
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain (2008) 2.40
Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet (1998) 2.39
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci (2004) 2.16
Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A (1998) 2.14
Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron (2005) 2.11
Regional specificity of brain atrophy in Huntington's disease. Exp Neurol (1998) 2.02
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86
Widespread disruption of repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy at its target genes in Huntington's disease. J Neurosci (2007) 1.77
Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol Dis (2005) 1.69
Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci (2007) 1.66
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A (2000) 1.66
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci (2004) 1.58
Brain-derived neurotrophic factor in Huntington disease. Brain Res (2000) 1.57
Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res (1998) 1.54
Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci (2002) 1.40
Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol Neurodegener (2007) 1.39
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res (2005) 1.35
Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J Med Genet (1991) 1.35
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet (2002) 1.33
Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol (2007) 1.32
Expression of the striatal DARPP-32/ARPP-21 phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J Neurosci (1999) 1.27
Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis (2006) 1.25
Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci (2006) 1.25
Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol (2006) 1.23
Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci (2006) 1.21
Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol (1997) 1.18
Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol (2000) 1.11
Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem (2004) 1.10
Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene. Hum Mol Genet (2000) 1.10
Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease. Behav Brain Res (2007) 1.09
DARPP-32 genomic fragments drive Cre expression in postnatal striatum. Genesis (2005) 1.07
Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro. Neuroscience (1997) 1.03
Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience (2000) 1.02
Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience (1996) 1.00
A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis (2005) 0.99
Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. Mol Ther (2007) 0.94
Age-specific behavioral responses to psychostimulants in mice. Pharmacol Biochem Behav (2005) 0.92
Pyramidal cell loss in motor cortices in Huntington's disease. Neurobiol Dis (2002) 0.92
Motor abnormalities in staggerer mutant mice. Exp Brain Res (1987) 0.91
Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiol Dis (2006) 0.86
Motor abnormalities in weaver mutant mice. Exp Brain Res (1987) 0.83
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet (2009) 2.73
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction (2010) 1.71
Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci (2010) 1.58
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol (2010) 1.34
Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med (2005) 1.32
Direct interaction between causative genes of DYT1 and DYT6 primary dystonia. Ann Neurol (2010) 1.30
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener (2009) 1.18
Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics (2008) 1.18
Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis (2010) 1.14
Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J Neurosci (2010) 1.14
DARPP-32 genomic fragments drive Cre expression in postnatal striatum. Genesis (2005) 1.07
AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J Biol Chem (2007) 0.99
Alzheimer's presenilin 1 modulates sorting of APP and its carboxyl-terminal fragments in cerebral neurons in vivo. J Neurochem (2007) 0.97
In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum Mol Genet (2010) 0.96
Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem (2004) 0.95
Age-specific behavioral responses to psychostimulants in mice. Pharmacol Biochem Behav (2005) 0.92
The distribution of cocaine in mice differs by age and strain. Neurotoxicol Teratol (2004) 0.89
Altered synaptic structure in the hippocampus in a mouse model of Alzheimer's disease with soluble amyloid-β oligomers and no plaque pathology. Mol Neurodegener (2014) 0.89
Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast. J Alzheimers Dis (2012) 0.88
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis. Neurosci Lett (2005) 0.88
Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathology. Mol Neurodegener (2009) 0.85
Protein sorting motifs in the cytoplasmic tail of SorCS1 control generation of Alzheimer's amyloid-β peptide. J Neurosci (2013) 0.84
Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model. J Biol Chem (2013) 0.83
Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice. PLoS One (2012) 0.83
The role of pregnancy hormones in the regulation of Pdx-1 expression. Mol Cell Endocrinol (2005) 0.83
Prenatal exposure to cocaine decreases adenylyl cyclase activity in embryonic mouse striatum. Brain Res Dev Brain Res (2003) 0.83
17beta-Estradiol promotes striatal medium size spiny neuronal maturation in vitro. Neuroendocrinology (2004) 0.83
Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro (2011) 0.82
Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer's APP metabolism and phosphorylation of the Vps10-domain protein, SorL1. Mol Neurodegener (2010) 0.81
Augmented D1 dopamine receptor signaling and immediate-early gene induction in adult striatum after prenatal cocaine. Biol Psychiatry (2008) 0.81
Trk: a neuromodulator of age-specific behavioral and neurochemical responses to cocaine in mice. J Neurosci (2008) 0.80
Alzheimer amyloid precursor aspartyl proteinase activity in CHAPSO homogenates of Spodoptera frugiperda cells. Alzheimer Dis Assoc Disord (2004) 0.80
Egr-1 induces DARPP-32 expression in striatal medium spiny neurons via a conserved intragenic element. J Neurosci (2012) 0.79
Dystonia type 6 gene product Thap1: identification of a 50 kDa DNA-binding species in neuronal nuclear fractions. Acta Neuropathol Commun (2014) 0.76
Phosphatidylinositide 3-kinase and protein kinase C zeta mediate retinoic acid induction of DARPP-32 in medium size spiny neurons in vitro. J Neurochem (2008) 0.76
Sumoylation of critical proteins in amyotrophic lateral sclerosis: emerging pathways of pathogenesis. Neuromolecular Med (2013) 0.76
Phenotyping dividing cells in mouse models of neurodegenerative basal ganglia diseases. BMC Neurosci (2013) 0.76
Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2. PLoS One (2013) 0.75